Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Baxter
Queensland Health
Merck
Farmers Insurance
Covington
Cantor Fitzgerald
Dow

Generated: January 24, 2019

DrugPatentWatch Database Preview

Lederle Company Profile

« Back to Dashboard

What is the competitive landscape for LEDERLE, and what generic and branded alternatives to LEDERLE drugs are available?

LEDERLE has ninety-six approved drugs.



Summary for Lederle
US Patents:0
Tradenames:49
Ingredients:48
NDAs:96

Drugs and US Patents for Lederle

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lederle SUPRAX cefixime FOR SUSPENSION;ORAL 050622-001 Apr 28, 1989 DISCN Yes No ➤ Sign Up ➤ Sign Up
Lederle HYDROMOX quinethazone TABLET;ORAL 013264-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Lederle PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 072117-001 Jun 23, 1988 DISCN No No ➤ Sign Up ➤ Sign Up
Lederle ACETAMINOPHEN AND CODEINE PHOSPHATE acetaminophen; codeine phosphate TABLET;ORAL 087141-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Lederle LEDERCILLIN VK penicillin v potassium FOR SOLUTION;ORAL 060136-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Lederle SPIRONOLACTONE spironolactone TABLET;ORAL 087634-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Lederle DECLOMYCIN demeclocycline hydrochloride CAPSULE;ORAL 050262-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Lederle

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lederle ASENDIN amoxapine TABLET;ORAL 018021-004 Approved Prior to Jan 1, 1982 3,681,357 ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-004 Approved Prior to Jan 1, 1982 3,546,226 ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-001 Approved Prior to Jan 1, 1982 3,546,226 ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-003 Approved Prior to Jan 1, 1982 3,546,226 ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-002 Approved Prior to Jan 1, 1982 3,663,696 ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-003 Approved Prior to Jan 1, 1982 3,681,357 ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-002 Approved Prior to Jan 1, 1982 3,681,357 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for LEDERLE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Oral Suspension 500 mg/5 mL ➤ Subscribe 2014-07-22
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Healthtrust
McKinsey
Cantor Fitzgerald
Harvard Business School
AstraZeneca
Covington
UBS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.